Abstract

A dysregulated or exacerbated inflammatory response is thought to be the key driver of the pathogenesis of severe disease caused by the mosquito-borne dengue virus (DENV). Compounds that restrict virus replication and modulate the inflammatory response could thus serve as promising therapeutics mitigating the disease pathogenesis. We and others have previously shown that macrophages, which are important cellular targets for DENV replication, differentiated in the presence of bioactive vitamin D (VitD3) are less permissive to viral replication, and produce lower levels of pro-inflammatory cytokines. Therefore, we here evaluated the extent and kinetics of innate immune responses of DENV-2 infected monocytes differentiated into macrophages in the presence (D3-MDMs) or absence of VitD3 (MDMs). We found that D3-MDMs expressed lower levels of RIG I, Toll-like receptor (TLR)3, and TLR7, as well as higher levels of SOCS-1 in response to DENV-2 infection. D3-MDMs produced lower levels of reactive oxygen species, related to a lower expression of TLR9. Moreover, although VitD3 treatment did not modulate either the expression of IFN-α or IFN-β, higher expression of protein kinase R (PKR) and 2'-5'-oligoadenylate synthetase 1 (OAS1) mRNA were found in D3-MDMs. Importantly, the observed effects were independent of reduced infection, highlighting the intrinsic differences between D3-MDMs and MDMs. Taken together, our results suggest that differentiation of MDMs in the presence of VitD3 modulates innate immunity in responses to DENV-2 infection.

Highlights

  • With an estimated 390 million infections every year, the dengue virus (DENV) is one of the most frequently transmitted arboviruses in tropical and subtropical countries [1]

  • We have previously demonstrated that monocyte-derived macrophages (MDMs) differentiated in the presence of VitD3 (D3-MDMs) are more resistant to DENV-2 infection, due to a decreased expression of mannose receptor (MR) and reduced viral uptake [17]

  • VitD3 modulates the expression of RIG I, TLR7, TLR3 and TLR4 in D3MDMs infected with DENV-2

Read more

Summary

Introduction

With an estimated 390 million infections every year, the dengue virus (DENV) is one of the most frequently transmitted arboviruses in tropical and subtropical countries [1]. Denvaxia, the only available vaccine approved in 11 countries, is only partially effective [3]. The availability of an effective therapeutic strategy is, an important goal, considering that almost 50% of the human population lives in zones with a risk of transmission [1]. The mechanism underlying the aberrant inflammatory response is not fully understood, the infection-induced excessive production of proinflammatory cytokines is known to promote endothelial permeability and damage to endothelial integrity, thought to be responsible for severe disease [4]. Ameliorating exacerbated inflammation is considered a key aim of therapeutic strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call